67 related articles for article (PubMed ID: 23495705)
1. Development of genomic markers that predict response to molecularly targeted antileukemic therapy.
Raponi M; Harousseau JL
Expert Opin Med Diagn; 2008 Apr; 2(4):361-72. PubMed ID: 23495705
[TBL] [Abstract][Full Text] [Related]
2. Molecular tumor profiling for prediction of response to anticancer therapies.
Walther Z; Sklar J
Cancer J; 2011; 17(2):71-9. PubMed ID: 21427550
[TBL] [Abstract][Full Text] [Related]
3. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
4. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
5. Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes.
Plass C; Byrd JC; Raval A; Tanner SM; de la Chapelle A
Br J Haematol; 2007 Dec; 139(5):744-52. PubMed ID: 17961188
[TBL] [Abstract][Full Text] [Related]
6. Deregulation of signaling pathways in acute myeloid leukemia.
Scholl C; Gilliland DG; Fröhling S
Semin Oncol; 2008 Aug; 35(4):336-45. PubMed ID: 18692684
[TBL] [Abstract][Full Text] [Related]
7. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
[TBL] [Abstract][Full Text] [Related]
8. Genomics in myeloid leukemias: an array of possibilities.
Bullinger L; Döner H; Pollack JR
Rev Clin Exp Hematol; 2005 Jun; 9(1):E2. PubMed ID: 16027104
[TBL] [Abstract][Full Text] [Related]
9. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
10. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.
Thompson MC; Fuller C; Hogg TL; Dalton J; Finkelstein D; Lau CC; Chintagumpala M; Adesina A; Ashley DM; Kellie SJ; Taylor MD; Curran T; Gajjar A; Gilbertson RJ
J Clin Oncol; 2006 Apr; 24(12):1924-31. PubMed ID: 16567768
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling as a tool for basic analysis and clinical application of human cancer.
García-Escudero R; Paramio JM
Mol Carcinog; 2008 Aug; 47(8):573-9. PubMed ID: 18324660
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.
Ausborn NL; Le QT; Bradley JD; Choy H; Dicker AP; Saha D; Simko J; Story MD; Torossian A; Lu B
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e453-64. PubMed ID: 22520478
[TBL] [Abstract][Full Text] [Related]
13. Therapy of acute myeloid leukemia: towards a patient-oriented, risk-adapted approach.
Mandelli F; Petti MC; Lo Coco F
Haematologica; 1998 Nov; 83(11):1015-23. PubMed ID: 9864924
[TBL] [Abstract][Full Text] [Related]
14. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
15. [Genomic markers and anticancer chemotherapy].
Nishiyama M
Gan To Kagaku Ryoho; 2008 Feb; 35(2):194-9. PubMed ID: 18281756
[TBL] [Abstract][Full Text] [Related]
16. Genomic approaches to outcome prediction in prostate cancer.
Febbo PG
Cancer; 2009 Jul; 115(13 Suppl):3046-57. PubMed ID: 19544546
[TBL] [Abstract][Full Text] [Related]
17. The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches.
Vitagliano O; Addeo R; D'Angelo V; Indolfi C; Indolfi P; Casale F
Expert Rev Hematol; 2013 Oct; 6(5):587-97. PubMed ID: 24083449
[TBL] [Abstract][Full Text] [Related]
18. Advances in treatment of lung cancer with targeted therapy.
Cagle PT; Chirieac LR
Arch Pathol Lab Med; 2012 May; 136(5):504-9. PubMed ID: 22540298
[TBL] [Abstract][Full Text] [Related]
19. [Response predictive biomarkers to targeted therapies in oncology].
Harlé A; Merlin JL
Ann Biol Clin (Paris); 2013 Nov; 71():89-97. PubMed ID: 24235332
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks.
Roukos DH
Pharmacogenomics J; 2011 Apr; 11(2):81-92. PubMed ID: 20975737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
